OS Therapies Incorporated (OSTX) 10-Year Financial Performance & Capital Metrics

OSTX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutOS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.Show more

Revenue $0
EBITDA -$7M -57.0%
Net Income -$9M -14.0%
EPS (Diluted) -0.52 -33.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -1094.65%
ROIC -
Debt/Equity -
Interest Coverage -3.32 -163.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 12 (bottom 12%)
✗Trading more than 30% below 52-week high
✗Expensive at 37.5x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-148.55%

EPS CAGR

10Y-

5Y-

3Y-

TTM-50.83%

ROCE

10Y Avg-747.55%

5Y Avg-747.55%

3Y Avg-747.55%

Latest-747.55%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0
Revenue Growth %	-	-	-	-	-
Cost of Goods Sold+	4.25K	1.16M	805	4.22K	2.78K
COGS % of Revenue	-	-	-	-	-
Gross Profit+	-4.25K	-1.16M	-805	-4.22K	-2.78K
Gross Margin %	-	-	-	-	-
Gross Profit Growth %	-	-271.86%	1%	-4.24%	0.34%
Operating Expenses+	1.4K	3.68M	4.45M	4.34M	6.81M
OpEx % of Revenue	-	-	-	-	-
Selling, General & Admin	795	1.5M	1.15M	1.12M	3.97M
SG&A % of Revenue	-	-	-	-	-
Research & Development	602	2.17M	3.29M	3.22M	2.84M
R&D % of Revenue	-	-	-	-	-
Other Operating Expenses	0	0	1.21K	5.15K	0
Operating Income+	-5.65K	-4.84M	-4.45M	-4.34M	-6.81M
Operating Margin %	-	-	-	-	-
Operating Income Growth %	-	-855.62%	0.08%	0.02%	-0.57%
EBITDA+	-5.65K	-4.84M	-4.45M	-4.34M	-6.81M
EBITDA Margin %	-	-	-	-	-
EBITDA Growth %	-	-855.48%	0.08%	0.02%	-0.57%
D&A (Non-Cash Add-back)	0	805	805	4.22K	2.78K
EBIT	-5.65K	-4.84M	-4.45M	-4.34M	-6.83M
Net Interest Income+	-380.5M	-2.58M	-1.81M	-3.45M	-2.05M
Interest Income	81.28M	0	0	0	0
Interest Expense	461.79M	2.58M	1.81M	3.45M	2.05M
Other Income/Expense	-381	-2.58M	-1.81M	-3.45M	-2.07M
Pretax Income+	-6.03K	-7.42M	-6.25M	-7.79M	-8.88M
Pretax Margin %	-	-	-	-	-
Income Tax+	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%
Net Income+	-6.03K	-7.42M	-6.25M	-7.79M	-8.88M
Net Margin %	-	-	-	-	-
Net Income Growth %	-	-1230.17%	0.16%	-0.25%	-0.14%
Net Income (Continuing)	-6.03K	-7.42M	-6.25M	-7.79M	-8.88M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.00	-0.33	-0.28	-0.39	-0.52
EPS Growth %	-	-	0.15%	-0.39%	-0.33%
EPS (Basic)	-0.00	-0.33	-0.28	-0.39	-0.52
Diluted Shares Outstanding	8.42M	23.1M	23.1M	20.05M	20.87M
Basic Shares Outstanding	8.42M	23.1M	23.1M	20.05M	20.87M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.68B	312.81K	496.83K	790.03K	5.53M
Cash & Short-Term Investments	1.23B	80.79K	171.48K	38.98K	5.53M
Cash Only	1.23B	80.79K	171.48K	38.98K	5.53M
Short-Term Investments	0	0	0	0	0
Accounts Receivable	430.49M	231.07K	1.15K	0	0
Days Sales Outstanding	-	-	-	-	-
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	12.8M	0	324.21K	751.05K	0
Total Non-Current Assets+	1.95M	13.08K	12.27K	8.05K	5.27K
Property, Plant & Equipment	1.95M	13.08K	12.27K	8.05K	5.27K
Fixed Asset Turnover	-	-	-	-	-
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0
Total Assets+	1.68B	325.89K	509.11K	798.08K	5.54M
Asset Turnover	-	-	-	-	-
Asset Growth %	-	-1%	0.56%	0.57%	5.94%
Total Current Liabilities+	2.1B	3.5M	6.15M	24.71M	4.63M
Accounts Payable	40K	856.52K	1.23M	2.72M	1.66M
Days Payables Outstanding	3.44K	269.59	555.5K	234.86K	218.22K
Short-Term Debt	871.25M	0	0	14.61M	0
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	809.03M	1.61M	3.04M	4.71M	2.35M
Current Ratio	0.80x	0.09x	0.08x	0.03x	1.20x
Quick Ratio	0.80x	0.09x	0.08x	0.03x	1.20x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	5.9B	8.28M	11.92M	100K	100K
Long-Term Debt	5.9B	7.07M	10.35M	0	0
Capital Lease Obligations	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	0	1.11M	1.47M	0	100K
Total Liabilities	8B	11.78M	18.07M	24.81M	4.73M
Total Debt+	6.77B	7.07M	10.35M	14.61M	0
Net Debt	5.54B	6.99M	10.18M	14.57M	-5.53M
Debt / Equity	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-0.00x	-1.87x	-2.46x	-1.26x	-3.32x
Total Equity+	-6.33B	-11.45M	-17.56M	-24.02M	811.49K
Equity Growth %	-	1%	-0.53%	-0.37%	1.03%
Book Value per Share	-751.22	-0.50	-0.76	-1.20	0.04
Total Shareholders' Equity	-6.33B	-11.45M	-17.56M	-24.02M	811.49K
Common Stock	8.84M	9.98K	4.99K	5.34K	20.87K
Retained Earnings	-6.34B	-15.22M	-21.6M	-29.52M	-40.4M
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	0	0	0	0
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.41B	-4.4M	-3.79M	-3.01M	-7.28M
Operating CF Margin %	-	-	-	-	-
Operating CF Growth %	-	1%	0.14%	0.21%	-1.42%
Net Income	-6.03B	-7.42M	-6.25M	-7.79M	-8.88M
Depreciation & Amortization	67K	805	805	4.22K	2.78K
Stock-Based Compensation	0	0	0	0	268.3K
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	2.65B	2.44M	1.51M	2.76M	1.46M
Working Capital Changes	964.39M	574.67K	947.33K	2.02M	-129.64K
Change in Receivables	0	0	0	0	0
Change in Inventory	0	0	0	0	0
Change in Payables	9K	856.48K	216.43K	1.35M	-1.05M
Cash from Investing+	158.29M	200.47K	230.88K	1.15K	0
Capital Expenditures	-2.01M	-11.93K	0	0	0
CapEx % of Revenue	-	-	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	160.3M	212.41K	230.88K	1.15K	0
Cash from Financing+	3.48B	3.05M	3.65M	2.87M	12.78M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	-31.25M
Share Repurchases	-	-	-	-	-
Other Financing	0	100K	-172.02K	-284.18K	31.25M
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-2.42B	-4.41M	-3.79M	-3.01M	-7.28M
FCF Margin %	-	-	-	-	-
FCF Growth %	-	1%	0.14%	0.21%	-1.42%
FCF per Share	-286.76	-0.19	-0.16	-0.15	-0.35
FCF Conversion (FCF/Net Income)	400386.10x	0.59x	0.61x	0.39x	0.82x
Interest Paid	0	10K	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-	-1094.65%
Interest Coverage	-0.00x	-1.87x	-2.46x	-1.26x	-3.32x
FCF Conversion	400386.10x	0.59x	0.61x	0.39x	0.82x

Frequently Asked Questions

Growth & Financials

OS Therapies Incorporated (OSTX) grew revenue by 0.0% over the past year. Growth has been modest.

OS Therapies Incorporated (OSTX) reported a net loss of $18.3M for fiscal year 2024.

Dividend & Returns

Yes, OS Therapies Incorporated (OSTX) pays a dividend with a yield of 100.00%. This makes it attractive for income-focused investors.

OS Therapies Incorporated (OSTX) has a return on equity (ROE) of -1094.6%. Negative ROE indicates the company is unprofitable.

OS Therapies Incorporated (OSTX) had negative free cash flow of $13.3M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener